FDA pauses enrollment in Biohaven's opakalim trials; pivotal readout remains on track

The FDA has issued a partial clinical hold on Biohaven's opakalim trials, pausing new patient enrollment pending additional nonclinical metabolite studies, while dosing continues for already enrolled patients and the pivotal trial readout timeline remains unaffected.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.